Xiaoming Xie

11.0k total citations · 3 hit papers
150 papers, 7.1k citations indexed

About

Xiaoming Xie is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Xiaoming Xie has authored 150 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Molecular Biology, 68 papers in Cancer Research and 62 papers in Oncology. Recurrent topics in Xiaoming Xie's work include MicroRNA in disease regulation (25 papers), Cancer-related molecular mechanisms research (23 papers) and Breast Cancer Treatment Studies (20 papers). Xiaoming Xie is often cited by papers focused on MicroRNA in disease regulation (25 papers), Cancer-related molecular mechanisms research (23 papers) and Breast Cancer Treatment Studies (20 papers). Xiaoming Xie collaborates with scholars based in China, United States and Hong Kong. Xiaoming Xie's co-authors include Hailin Tang, Xinhua Xie, Lu Yang, Yutian Zou, Yanan Kong, Shaoquan Zheng, Weidong Wei, Jiaoli Guo, Laisheng Li and Cailu Song and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Xiaoming Xie

147 papers receiving 7.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery

2022 248 citations Yutian Zou, Jindong Xie et al. profile →
N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer

2022 167 citations Yutian Zou, Shaoquan Zheng et al. Nature Communications profile →
Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies

2024 50 citations Jindong Xie, Xinpei Deng et al. SHILAP Revista de lepidopterología profile →

Peers

Countries citing papers authored by Xiaoming Xie

Since Specialization

Citations

This map shows the geographic impact of Xiaoming Xie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoming Xie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoming Xie more than expected).

Fields of papers citing papers by Xiaoming Xie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaoming Xie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoming Xie. The network helps show where Xiaoming Xie may publish in the future.

Co-authorship network of co-authors of Xiaoming Xie

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaoming Xie. A scholar is included among the top collaborators of Xiaoming Xie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaoming Xie. Xiaoming Xie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	MYCN amplification defines an aggressive phenotype in IDH‐mutant gliomas 2025 ·The Journal of Pathology Clinical Research ·Xiaoming Xie, Yan Qin, Fang Wang, (unknown), Yujie Zhang, Shaoyan Xi	0
2	Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies breakdown → 2024 ·SHILAP Revista de lepidopterología ·Jindong Xie, (unknown), Xinpei Deng, Yuhui Tang, Shaoquan Zheng, Xueqi Ou, Hailin Tang, Xiaoming Xie, (unknown), Yutian Zou	50
3	[Medication rules of traditional Chinese medicine compounds for pain]. 2023 ·PubMed ·Xinyi Li, (unknown), (unknown), (unknown), Xiaoming Xie, Guihua Tian	13
4	N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer breakdown → 2022 ·Nature Communications ·Yutian Zou, Shaoquan Zheng, Xinhua Xie, Feng Ye, Xiaoqian Hu, Zhi Tian, Shumei Yan, Lu Yang, Yanan Kong, Yuhui Tang, W. H. Tian, Jindong Xie, Xinpei Deng, Yan Zeng, Zhe‐Sheng Chen, Hailin Tang, Xiaoming Xie	167
5	Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer 2022 ·Cancer Control ·Jindong Xie, Yutian Zou, Ting Gao, Liming Xie, Duxun Tan, Xiaoming Xie	16
6	Predictive Nomogram of Subsequent Liver Metastasis After Mastectomy or Breast-Conserving Surgery in Patients With Nonmetastatic Breast Cancer 2021 ·Cancer Control ·Anli Yang, Weikai Xiao, Shaoquan Zheng, Yanan Kong, Yutian Zou, Mingyue Li, Feng Ye, Xiaoming Xie	5
7	The value of neutrophil-to-lymphocyte ratio for response and prognostic effect of neoadjuvant chemotherapy in solid tumors: A systematic review and meta-analysis 2018 ·Journal of Cancer ·Xuan Li, Danian Dai, Qing Chen, Hailin Tang, Xiaoming Xie, Weidong Wei	49
8	Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: a population-based study 2018 ·Cancer Management and Research ·Weikai Xiao, Shaoquan Zheng, Anli Yang, Xingcai Zhang, Yutian Zou, Hailin Tang, Xiaoming Xie	121
9	Transcriptomic analyses identify key differentially expressed genes and clinical outcomes between triple-negative and non-triple-negative breast cancer 2018 ·Cancer Management and Research ·Bo Chen, Hailin Tang, Xi Chen, Guochun Zhang, Yulei Wang, Xiaoming Xie, Ning Liao	38
10	Diallyl Disulfide Inhibits Breast Cancer Stem Cell Progression and Glucose Metabolism by Targeting CD44/PKM2/AMPK Signaling 2018 ·Current Cancer Drug Targets ·Xinhua Xie, (unknown), Xiaojia Huang, Hailin Tang, Feng Ye, Lu Yang, Xiaofang Guo, Zhi Tian, Xiaofang Xie, Cheng Peng, Xiaoming Xie	31
11	Risk factors and survival outcomes in patients with breast cancer and lung metastasis: a population‐based study 2018 ·Cancer Medicine ·Weikai Xiao, Shaoquan Zheng, Peng Liu, Yutian Zou, Xinhua Xie, Ping Yu, Hailin Tang, Xiaoming Xie	67
12	Neoisoliquiritigenin Inhibits Tumor Progression by Targeting GRP78-β- catenin Signaling in Breast Cancer 2018 ·Current Cancer Drug Targets ·Hailin Tang, Peng Fu, Xiaojia Huang, Xinhua Xie, Bo Chen, Jiangang Shen, Fei Fei Gao, Jieshu You, Xiaoming Xie, Jianping Chen	12
13	Direct inhibition of ACTN4 by ellagic acid limits breast cancer metastasis via regulation of β-catenin stabilization in cancer stem cells 2017 ·Journal of Experimental & Clinical Cancer Research ·Neng Wang, Qi Wang, Hailin Tang, Fengxue Zhang, Yifeng Zheng, Shengqi Wang, Jin Zhang, Zhiyu Wang, Xiaoming Xie	58
14	POMC maintains tumor-initiating properties of tumor tissue-derived long-term-cultured breast cancer stem cells 2017 ·International Journal of Cancer ·Xiaoti Lin, Weiyu Chen, Fengqin Wei, Binhua P. Zhou, Mien‐Chie Hung, Xiaoming Xie	10
15	Targeted BikDD Expression Kills Androgen-Dependent and Castration-Resistant Prostate Cancer Cells 2014 ·Molecular Cancer Therapeutics ·Xiaoming Xie, Yanan Kong, Hailin Tang, Lu Yang, Jennifer L. Hsu, Mien‐Chie Hung	12
16	miR-185 Suppresses Tumor Proliferation by Directly Targeting E2F6 and DNMT1 and Indirectly Upregulating BRCA1 in Triple-Negative Breast Cancer 2014 ·Molecular Cancer Therapeutics ·Hailin Tang, Peng Liu, Lu Yang, Xinhua Xie, Ye Feng, Minqing Wu, Xiaoping Liu, Bo Chen, Lijuan Zhang, Xiaoming Xie	101
17	miR-200b and miR-200c as Prognostic Factors and Mediators of Gastric Cancer Cell Progression 2013 ·Clinical Cancer Research ·Hailin Tang, Min Deng, Yunyun Tang, Xinhua Xie, Jiaoli Guo, Yanan Kong, Feng Ye, Qi Su, Xiaoming Xie	145
18	Microrna-124 targets flotillin-1 to regulate proliferation and migration in breast cancer 2013 ·Molecular Cancer ·Laisheng Li, (unknown), Bo Wang, Dong Wang, Xinhua Xie, Linjing Yuan, Jiaoli Guo, Shaoyan Xi, Jie Gao, Xiaoti Lin, Yanan Kong, Xiangdong Xu, Hailin Tang, Xiaoming Xie, Min Liu	101
19	A novel hTERT promoter–driven E1A therapeutic for ovarian cancer 2009 ·Molecular Cancer Therapeutics ·Xiaoming Xie, Jennifer L. Hsu, Min Gew Choi, Weiya Xia, Hirohito Yamaguchi, Chun‐Te Chen, (unknown), Zhen Lü, Naoto T. Ueno, Judith K. Wolf, Robert C. Bast, Mien‐Chie Hung	30
20	EZC-Prostate Models Offer High Sensitivity and Specificity for Noninvasive Imaging of Prostate Cancer Progression and Androgen Receptor Action 2006 ·Cancer Research ·Mamatha Seethammagari, Xiaoming Xie, Norman M. Greenberg, David M. Spencer	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact